Delving into the Latest Updates on Neovasculgen with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms

cambiogenplasmid, Vascular endothelial growth factor gene therapy, VEGF gene therapy

+ [1]

Target

VEGF-A

Action

stimulants, inducers

Mechanism

VEGF-A stimulants(Vascular endothelial growth factor A stimulants), Angiogenesis inducers

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Peripheral Arterial Disease

Inactive Indication

Diabetic foot ulcer

Originator Organization

Artgen Biotech PJSC

Active Organization

Artgen Biotech PJSC

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Russia (07 Dec 2011),

Peripheral Arterial Disease

Regulation-

Login to view timeline

"Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Study of the Efficacy and Safety of the Drug Neovasculgen® Lyophilisate for the Preparation of a Solution for Intramuscular Administration 1.2 mg", Manufacturer Federal State Budgetary Institution "NMITs of Hematology" of the Ministry of Health of the Russian Federation, Russia in Patients With Diabetic Foot Syndrome"

The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.

Start Date11 Feb 2025

Sponsor / Collaborator-

NCT06473740

/ RecruitingPhase 4IIT

Multicenter Randomized Prospective Controlled Trial of the Clinical Effectiveness of a Best Endovascular Treatment Versus a Best Endovascular Treatment in Combination With Gene Therapy for Severe Limb Ischemia

GENEVA is the world's first multicenter, randomized, prospective, controlled trial of the clinical effectiveness of best endovascular treatment versus best endovascular treatment combined with gene therapy for severe lower limb ischemia (Rutherford categories 4 and 5). The researchers hypothesized that the combination treatment would significantly reduce the number of re-interventions on the operated segment and high amputations, and also significantly increase the time interval between re-interventions.

Start Date20 Jun 2024

Sponsor / Collaborator-

NCT07391306

/ RecruitingPhase 2/3

Double-blind, Placebo-controlled, Adaptive, Multicenter, Prospective, Randomized, Comparative, Parallel-group Study of the Efficacy and Safety of Neovasculgen (Plasmid Supercoiled Deoxyribonucleic Acid pCMV-VEGF165) in Painful Bladder Syndrome/Interstitial Cystitis (BPS/IC)

To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis and the prevention of secondary bladder shrinkage with a decrease in its volume.

Start Date16 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Neovasculgen

Login to view more data

100 Translational Medicine associated with Neovasculgen

Login to view more data

100 Patents (Medical) associated with Neovasculgen

Login to view more data

9

Literatures (Medical) associated with Neovasculgen

01 Jan 2025·Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Neovasculgen® – has its effectiveness been proven? (Audiatur et altera pars)

Letter

Author: Vachev, A N ; Karpenko, A A ; Bazylev, V V ; Troitskiy, A V

01 Jan 2020·Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Ways of limbs salvage in postoperative period of treatment of complications of diabetic foot syndrome

Article

Author: Krivoshchekov, E P ; Rodnianskiĭ, D V ; Aliapyshev, G S ; Romanov, V E ; El'shin, E B

01 Sep 2018·Therapeutic advances in cardiovascular disease

Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication

Article

Author: Bozo, Ilia ; Mzhavanadze, Nina ; Suchkov, Igor ; Staroverov, Ilia ; Kalinin, Roman ; Plaksa, Igor ; Deev, Roman ; Isaev, Artur ; Chervyakov, Yuriy

100 Deals associated with Neovasculgen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Neovasculgen	V09G	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peripheral Arterial Disease	Russia	Artgen Biotech PJSC	07 Dec 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Clinical	Russia	Artgen Biotech PJSC	01 Aug 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03068585 (Pubmed \| Ther Adv Cardiovasc Dis)	Phase 2/3	Intermittent Claudication \| Peripheral Arterial Disease	100	pl-VEGF165	mqtazekfrt(vnssonjfwo) = vcwptdwpci ygfkvbwczf (aealayalju )	Positive	01 Sep 2018
NCT02369809 (Pubmed \| Am J Cardiovasc Drugs)	Phase 4	Peripheral Arterial Disease	210	Control group	feapxjghxq(iwiewhuzgi) = diurzdopis eiyqsumbii (mislhdqxvi )	Positive	01 Jun 2017
NCT02369809 (Pubmed \| Am J Cardiovasc Drugs)	Phase 4	Peripheral Arterial Disease	210	Treatment group	feapxjghxq(iwiewhuzgi) = gxdkfxsvad eiyqsumbii (mislhdqxvi )	Positive	01 Jun 2017